A study on the effects of exposure to benzene on the activity of immunoglobulin E / 中华劳动卫生职业病杂志

Objective@#To analyze the level of immunoglobulin E (IgE) changes with benzene exposure workers.@*Methods@#Firstly, through occupational health monitoring, 68 hospitalized cases were discovered who were suspected chronic benzene poisoning. Secondly, according to the GBZ68-2013《The diagnosis of occupational benzene poisoning》standard diagnosis and indexing, 68 cases were divided into the benzene poisoning group (n= 29) and the benzene exposure group (n=39) . 50 cases of healthy workers without benzene exposure were for the control group. Use the immune luminescence method to detect IgE levels. Thirdly, Case-control study was used, observing IgE changes though the three groups by statistical analysis.@*Results@#Compared with control group, the level of leukocyte、neutrophil and IgE was drop in benzene exposure group with statistically significant (P<0.05) . Compared with benzene exposure group, IgE of benzene poisoning group was rise, with statistically significant (P<0.05) , IgE of mild benzene poisoning group rise the most obvious, with statistically significant (P<0.05) . Compared with benzene exposure group, IgE of moderate benzene poisoning group was drop, without statistically significant (P>0.05) .@*Conclusion@#Benzene occupational exposure can induce immunosuppression, IgE decreases, and reduces immune surveillance. The response of the IgE level in the mild benzene poisoning patients was significantly elevated, whether it is protective response of the body immune function needs to be studied further investigated.

Antibody to FcεRIα Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation

PURPOSE: High-affinity receptor I (FcεRI) on mast cells and basophils plays a key role in the immunoglobulin E (IgE)-mediated type I hypersensitivity mediated by allergen cross-linking of the specific IgE-FcεRI complex. Thus, prevention of IgE binding to FcεRI on these cells is an effective therapy for allergic disease. We have developed a strategy to disrupt IgE binding to FcεRI using an antibody targeting FcεRIα. MATERIALS AND METHODS: Fab fragment antibodies, which lack the Fc domain, with high affinity and specificity for FcεRIα and effective inhibitory activity against IgE-FcεRI binding were screened. IgE-induced histamine, β-hexosaminidase and Ca2+ release in basophils were determined by ELISA. A B6.Cg-Fcer1a(tm1Knt) Tg(FCER1A)1Bhk/J mouse model of passive cutaneous anaphylaxis (PCA) was used to examine the inhibitory effect of NPB311 on allergic skin inflammation. RESULTS: NPB311 exhibited high affinity to human FcεRIα (KD=4 nM) and inhibited histamine, β-hexosaminidase and Ca2+ release in a concentration-dependent manner in hFcεRI-expressing cells. In hFcεRIα-expressing mice, dye leakage was higher in the PCA group than in controls, but decreased after NPB311 treatment. NPB311 could form a complex with FcεRIα and inhibit the release of inflammation mediators. CONCLUSION: Our approach for producing anti-FcεRIα Fab fragment antibody NPB311 may enable clinical application to a therapeutic pathway in IgE/FcεRI-mediated diseases.

Antibody to FcεRIα Suppresses Immunoglobulin E Binding to High-Affinity Receptor I in Allergic Inflammation

PURPOSE: High-affinity receptor I (FcεRI) on mast cells and basophils plays a key role in the immunoglobulin E (IgE)-mediated type I hypersensitivity mediated by allergen cross-linking of the specific IgE-FcεRI complex. Thus, prevention of IgE binding to FcεRI on these cells is an effective therapy for allergic disease. We have developed a strategy to disrupt IgE binding to FcεRI using an antibody targeting FcεRIα. MATERIALS AND METHODS: Fab fragment antibodies, which lack the Fc domain, with high affinity and specificity for FcεRIα and effective inhibitory activity against IgE-FcεRI binding were screened. IgE-induced histamine, β-hexosaminidase and Ca2+ release in basophils were determined by ELISA. A B6.Cg-Fcer1a(tm1Knt) Tg(FCER1A)1Bhk/J mouse model of passive cutaneous anaphylaxis (PCA) was used to examine the inhibitory effect of NPB311 on allergic skin inflammation. RESULTS: NPB311 exhibited high affinity to human FcεRIα (KD=4 nM) and inhibited histamine, β-hexosaminidase and Ca2+ release in a concentration-dependent manner in hFcεRI-expressing cells. In hFcεRIα-expressing mice, dye leakage was higher in the PCA group than in controls, but decreased after NPB311 treatment. NPB311 could form a complex with FcεRIα and inhibit the release of inflammation mediators. CONCLUSION: Our approach for producing anti-FcεRIα Fab fragment antibody NPB311 may enable clinical application to a therapeutic pathway in IgE/FcεRI-mediated diseases.

Anti-IgE na urticária crônica / Anti-IgE in chronic urticaria

A urticária é uma condição frequente; consiste de lesões eritematopapulosas pruriginosas, isoladas ou agrupadas, fugazes, geralmente circulares, podendo variar em forma e tamanho. Convencionalmente, a urticária pode ser dividida, quanto a sua duração, em duas formas: aguda e crônica. Na forma crônica as lesões estão presentes diariamente ou quase diariamente, permanecendo menos de 24 horas na maior parte dos casos, durante um período superior a seis semanas, frequentemente tendo impacto na qualidade de vida. A anti-IgE é um anticorpo monoclonal humanizado aprovado para o uso em asma de difícil controle. Atualmente, várias linhas de evidência indicam que a anti-IgE pode ser benéfica no tratamento da urticária espontânea crônica e física. Neste artigo revisamos as principais e atuais publicações sobre o uso de anti-IgE para o tratamento da urticária crônica refratária aos tratamentos convencionais. Outros estudos ainda são necessários para melhor compreender os mecanismos envolvidos na resposta favorável a esta terapia.

Urticaria is a common condition, consisting of fleeting erythematopapulous pruritic lesions, appearing isolated or grouped, usually circular, but varying in shape and size. Conventionally, hives can be divided into acute and chronic, according to their duration. In the chronic form, lesions are present daily or almost daily, remaining present for less than 24 hours in most cases, over a period longer than 6 weeks, usually with an impact on quality of life. Anti-immunoglobulin E (anti-IgE) is a humanized monoclonal antibody approved for use in difficult-to-control asthma. Currently, several lines of evidence indicate that anti-IgE antibodies can be beneficial in the treatment of chronic spontaneous and physical urticaria. In this paper, we review major and current publications on the use of anti-IgE for the treatment of chronic urticaria refractory to conventional treatment. Further studies are needed to better understand the mechanisms involved in the favorable response of chronic urticaria to this therapy.

Serum immunoglobulin E (IgE) levels and dietary intake of Korean infants and young children with atopic dermatitis

Atopic dermatitis (AD) has become a serious epidemic in Korean children. We aimed to investigate the association between vitamin C, E and other nutrients, and serum total IgE/specific IgE levels in children with AD. A total of 119 children (0-24 mo) diagnosed with AD were recruited for this cross-sectional study from a medical center in Seoul. A 24 h recall was used to assess dietary intakes. Serum total and six food-allergen specific IgE levels were measured by CAP-FEIA. Serum vitamin E was also measured but only in 25 out of the total 119 participants. Multiple linear regression analysis was performed to estimate the coefficients between serum IgE levels and dietary intake as well as serum vitamin E. Serum vitamin E levels showed a significantly inverse association with serum total IgE and all specific IgE levels (P < 0.05). Fat intake was inversely related with specific-IgEs for egg whites, milk, buck wheat, soy, and peanuts (P < 0.05). Positive associations were found between carbohydrate (CHO) intake and total IgE and specific IgEs to egg whites, milk, soy, and peanuts (P < 0.05). Vitamin C, E and n-3/n-6 fatty acids were not related with serum total IgE and specific IgE levels except for the association between buck wheat and vitamin E. In addition, there were no significant differences between males and females in dietary intake and serum IgE levels by student's t-test. Although dietary vitamin E showed no association with serum IgE levels, serum vitamin E drew a significant inverse relationship with serum IgE levels. The evidence seems to suggest that vitamin E may possibly lower total and specific-IgEs in children with AD, and that it is important to maintain a relatively high serum vitamin E level in children with AD.

Detection Rate of Allergen-Specific IgE by Multiple Antigen Simultaneous Test-Immunoblot Assay / 대한진단검사의학회지

BACKGROUND: A new multiple antigen simultaneous test (MAST) has recently been introduced that is simple, rapid, and economical, and requires a small amount of serum samples. We evaluated the MAST-immunoblot assay (AllergyScreen; R-Biopharm, Darmstadt, Germany) for its specific antigen detection rate, and the results were interpreted based on the cut-off levels of classes 0.5, 1.0, 2.0, and 3.0 and correlated with clinical information. METHODS: A total of 166 allergic patients were tested by AllergyScreen (AS) for 10 specific allergens and the results were compared with skin prick test (SPT, cut-off=2+) or specific IgE (cut-off=class 1) on Uni-CAP system (uCAP). Thirty-five healthy subjects considered as truly negative for all allergens were also tested by AS to get the best cut-off level using the receiver operating characteristics (ROC) curve analysis and to evaluate its clinical specificity. RESULTS: The sensitivities (AS/uCAP, 73-31% and AS/SPT, 27-63%), specificities (AS/uCAP, 89-100% and AS/SP, 81-97%), and agreements (AS/uCAP 71-82% and AS/SPT 77-80%) varied with the cut-offm levels used and allergens tested. The overall linear regression equation was Y=0.69X+0.10, R=0.81 (P0.5 class and efficiency was 82% (AS/uCAP) and 75% (AS/ SPT). However, 25 (71%) of the healthy subjects showed positive reactions (0.6-4.0 class) to at least one allergen. CONCLUSIONS: Using an appropriate cut-off, AS/uCAP showed the sensitivity, specificity, and agreement at an acceptable level, and similar or better results compared with previous reports on MAST/ SPT. The AS can be an efficient way of testing for specific allergens in the clinical laboratory or at the physician's office. But, in view of the positive reactions in the healthy subjects, a class of less than 4.0 on AS must be integrated with clinical information for an appropriate data interpretation.

Evaluation of effectiveness of antigen specific immunotherapy for patients with allergic rhinitis / 解放军医学杂志

Objective To evaluate the effectiveness of allergen specific immunotherapy (SIT) in the treatment of allergic rhinitis. Methods A total of 132 patients with seasonal ragweed allergic rhinitis were enrolled in this study. The patients were randomly divided into two groups. SIT group, in which 68 patients were treated with ragweed SIT for six months before July for 3 years. ST (symptomatic therapy) group, in which 64 patients were treated with ST during seasonal symptomatic period. The healthy control group included 40 subjects. The levels of serum total IgE (tIgE), specific IgE (sIgE), ECP, IgG and IL-4, IL-5, IFN-? were measured, and eosinophil numbers were counted. The symptom score, lung-function test and skin prick test were performed before and after the treatment. Results The elevated levels of tIgE, ECP, IL-4, IL-5 in the sera and eosinophil counts in peripheral blood of the patients were significantly reduced, whereas the levels of IgG and IFN-? were increased following SIT. The levels of serum sIgE were not changed in both SIT and ST groups. 30.88% of the patients were clinically cured, the effective rate was 41.18%, the improvement rate was 20.59% after SIT, and only in 7.39% of patients there was no clinical improvement. In 16.18% of patients there were mild side effects to SIT. In the ST group, there was on change in all the laboratory results and clinical symptoms, and 25% of the patients developed asthma. Conclusion SIT was able to improve the symptoms and laboratory results of the patients with allergic rhinitis. The results indicated that SIT may be an effective and safe therapy for patients with allergic rhinitis.